Phase II Trial Opens: AI-Guided Dose Personalisation for Lung SBRT — Precision Radiation Therapy Study

References

1. 1.Northwestern University. (2023). A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors [Clinical trial registration NCT05802186]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05802186
2. 2.Timmerman, R. D., Hu, C., Michalski, J. M., Bradley, J. C., Galvin, J., Johnstone, D. W., Choy, H., Bentzen, S., Xiao, Y., Yom, S. S., Paulus, R., & Bogart, J. A. (2018). Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncology, 4(9), 1287-1288. https://doi.org/10.1001/jamaoncol.2018.1258
3. 3.Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., Schellenberg, D., Ahmad, B., Senthi, S., Swaminath, A., Kopek, N., Liu, M., Moore, K., Currie, S., Schlijper, R., ... Senan, S. (2019). Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers. Nature Reviews Clinical Oncology, 16(3), 145-157. https://doi.org/10.1038/s41571-019-0282-1
4. 4.Guckenberger, M., Andratschke, N., Dieckmann, K., Hoogeman, M. S., Hoyer, M., Hurkmans, C., Tanadini-Lang, S., Lartigau, E., Méndez Romero, A., Senan, S., Verellen, D., & Marta, G. N. (2020). ESTRO ACROP Consensus Guideline on Implementation and Practice of Stereotactic Body Radiotherapy for Peripherally Located Early Stage Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 149, 99-106. https://doi.org/10.1016/j.radonc.2019.10.009
5. 5.Ball, D., Mai, G. T., Vinod, S., Babington, S., Ruben, J., Kron, T., Chesson, B., Herschtal, A., Vanevski, M., Rezo, A., Elder, C., Skala, M., Wirth, A., Wheeler, G., Lim, A., Shaw, M., Irving, L., & Solomon, B. (2019). Stereotactic Ablative Radiotherapy Versus Standard Radiotherapy in Stage 1 Non-Small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet Oncology, 20(4), 494-503. https://doi.org/10.1016/S1470-2045(19)30290-0